Scrip
ProStrakan/Endo's testosterone gel faces US setback
20 October 2009
Asher Mullard
Please Login to read the full article.
20 October 2009
Asher Mullard
The US FDA has issued a complete response letter to ProStrakan/ Endo Pharmaceutical over Fortesta (testosterone, 2% gel), which was filed for the treatment of men with hypogonadism.
"We remain confident that we will be able to reassure the FDA that Fortesta should be approved and our partner,...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Endo signs $210 million Fortigel deal with ProStrakan
- Testosterone gel transfer to children prompts FDA boxed warning
- Hopes high for Provenge to become first US-approved therapeutic cancer vaccine
- 2009 results preview: big pharma grapples to varying degrees of success with generic erosion
COMMENT
Other Informa Comment
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
